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Background and purpose: The risk of heart disease subsequent to breast cancer radiotherapy was exam-
ined with particular focus on women receiving anthracycline-containing chemotherapy.
Material and methods: Women diagnosed with early-stage breast cancer in Denmark, 1977–2005, were
identified from the register of the Danish Breast Cancer Cooperative Group, as was information on
cancer-directed treatment. Information on heart disease was sought from the Danish National Patient
and Cause of Death Registries. Incidence rate ratios were estimated comparing left-sided with right-
sided cancer (IRR, LvR), stratified by calendar year, age, and time since breast cancer radiotherapy.
Results: Among 19,464 women receiving radiotherapy, the IRR, LvR, was 1.11 (95% CI 1.03–1.20,
p = 0.005) for all heart disease and among those also receiving anthracyclines the IRR, LvR, was 1.32
(95% CI 1.02–1.70, p = 0.03). This risk was highest if the treatment was given before the age of 50 years
(IRR, LvR, 1.44, (95% CI 1.04–2.01) but there was no significant trend with age or time since treatment.
Conclusions: Radiotherapy for left-sided breast cancer is associated with a higher risk of heart disease
than for right-sided with the largest increases seen in women who also received anthracycline-
containing chemotherapy.
 2017 The Author(s). Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 123 (2017) 299–305
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
The benefits of adjuvant radiotherapy for breast cancer have
been demonstrated in randomized trials and include a substantial
reduction in disease recurrence and a moderate reduction in breast
cancer mortality after either breast conserving surgery or mastec-
tomy with axillary dissection in axillary node-positive patients
[1,2]. However, in these trials the overall benefit from radiotherapy
was reduced by an increased mortality from heart disease among
women randomized to radiotherapy [3].
Women irradiated for left-sided breast cancer receive higher
cardiac doses than women irradiated for right-sided breast cancer.
In a previous study of almost 35,000 breast cancer patients from
Denmark and Sweden for whom adjuvant radiotherapy was
indicated, an increased incidence of all heart disease, and also of
acute myocardial infarction, angina, pericarditis, and valvular heart
disease was reported in women with left-sided breast cancer
compared to women with right-sided breast cancer [4]. The Danish
women in that study were diagnosed with breast cancer during
1977–2000 and followed to 2006. For these women, the predomi-
nant chemotherapy was cyclophosphamide, methotrexate and
fluorouracil (CMF).
Anthracyclines, in the form of epirubicin, were first introduced
into adjuvant chemotherapy for breast cancer in Denmark in 1990
as part of the DBCG 89D-trial [5]. Anthracyclines have been
demonstrated to reduce breast cancer recurrence and mortality
[6] but are cardiotoxic, increasing the risk of cardiomyopathy and
congestive heart failure [7,8]. Women with pre-existing heart
disease, or who are at increased risk of heart disease, have a lower
threshold for developing cardiotoxicity and are unlikely to receive
adjuvant chemotherapy with anthracyclines. Therefore, the
harmful effect of anthracyclines on the heart cannot be assessed
by comparing women who did and did not receive it outside a
randomized trial. However, it is possible to investigate whether
the effect of radiotherapy on the heart is increased, when
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anthracyclines were also given, by comparing the incidence of
heart disease in women with left-sided and right-sided breast can-
cer who received both radiotherapy and anthracyclines.
Few women diagnosed with breast cancer prior to 2000
received anthracyclines, so the previous cohort study provided lit-
tle information regarding the effect of anthracyclines in addition to
radiotherapy. We have therefore extended this Danish cohort to
include breast cancer patients diagnosed up to the end of 2005
and followed for cardiac events until the end of 2013. In addition,
we have obtained information on which women were actually
given radiotherapy, rather than radiotherapy just being indicated,
and also on which women were actually given chemotherapy
and on the type of chemotherapy they received. The main aim of
this study is to assess the risk of heart disease following breast can-
cer radiotherapy, especially among women who also received
anthracycline-containing chemotherapy.
Methods
Material
Since 1977, the Danish Breast Cancer Cooperative Group (DBCG)
has maintained a register of all women diagnosed with early-stage
breast cancer in Denmark [9]. All Danish hospitals involved in the
diagnosis and treatment of breast cancer patients report to the
DBCG and its register is more than 95% complete. Women diag-
nosed with early-stage breast cancer from June 1977 to December
2005 were identified from the DBCG register. Women were
excluded if they had bilateral cancer or cancer of unknown lateral-
ity, had a previous diagnosis of invasive cancer (apart from non-
melanoma skin cancer), did not undergo surgery (e.g. had biopsy
only), were diagnosed with breast cancer after emigration from
Denmark or were aged less than 20 years or more than 80 years
at diagnosis. Information on tumour characteristics and details of
therapies actually received was also obtained from the DBCG reg-
ister. Using the unique personal identification numbers issued to
all Danish citizens, the DBCG register was linked with the Danish
Register of Causes of Death (RCD) [10] for deaths since 1977, and
the Danish National Patient Register (NPR) [11] for in-patient diag-
noses since 1977 and outpatient diagnoses since 1995. Information
was complete up to 31 December 2013. Information on prior car-
diac disease, defined as ICD10-codes I00-I52 (or the corresponding
ICD8-codes) at least 30 days before breast cancer diagnosis, was
identified from the NPR.
The study was approved by the Danish Data Protection Agency
and by the Danish Health and Medicines Authority.
Statistical analysis
Descriptive analyses were conducted by tabulating the total
number of women, and the number who received radiotherapy,
according to breast cancer laterality and each of a number of other
characteristics. For every value of each characteristic, a Mantel–
Haenszel X2-test of whether the percentage given radiotherapy
was the same for women with left-sided and right-sided cancer
was conducted [12]. For further analyses, each woman’s contribu-
tion to the person-years at risk was calculated from six months
after the date of breast cancer diagnosis and until the earliest of:
diagnosis of any heart disease, 90th birthday, death, emigration,
or 31 December 2013. For each endpoint of interest (all heart dis-
ease, ischemic heart disease, etc.) the total number of observed
events and the person-years at risk were tabulated by calendar
year of radiotherapy (starting from 1977–1980, then in 5-year
groups), age at radiotherapy (starting from 20–24, then in 5-year
groups) and time since radiotherapy (in 5-year groups). Tabula-
tions were made for all women combined and for women in vari-
ous different treatment categories. For women given radiotherapy,
separate tabulations were made according to age at radiotherapy
and years since radiotherapy. Incidence rate ratios comparing
women in different categories, stratified by year, age, and time
since breast cancer radiotherapy (all in 5-year groups), were esti-
mated by logistic regression. To account for the differing numbers
of women with left-sided and right-sided breast cancer, a variable
taking the value of the ratio, left versus right, of the number of
years at risk was included in the model, with the coefficient con-
strained to one. Tests of whether an individual rate ratio differed
from one, of the homogeneity of the rate ratio across several differ-
ent groups of women (for example those receiving different adju-
vant medical treatments), and also tests for a trend in the rate
ratio across several groups of women were based on the logarithms
of the estimated rate ratios and their estimated variances.
Calculations were performed using Stata version 13 [13]
Results
Between 1977 and 2005, 71,423 women were registered with a
diagnosis of breast cancer by the DBCG. A total of 11,267 patients
were excluded, leaving 60,156 women (Fig. 1). These women
accrued 817,212 person-years, with a median follow up of
10.5 years (interquartile range 4.5–16.3 years).
When all 60,156 women were considered, the incidence rate
ratio comparing women with left-sided breast cancer to women
with right-sided breast cancer (IRR, LvR) for all heart disease was
1.05 (95% confidence interval (CI) 1.01–1.09, p = 0.01, Table 1).
When the women were subdivided according to radiotherapy sta-
tus, the IRR, LvR for the 19,464 for who received radiotherapy, was
higher, at 1.11 (95% CI 1.03–1.20) and the significance level was
more extreme (p = 0.005). In contrast, among women whose status
was recorded in the DBCG as radiotherapy not indicated, radiother-
apy indicated but not recorded, or radiotherapy unknown, the IRRs,
LvR, were closer to unity and none were significantly increased.
Among the 19,464 women (32.4%) who received radiotherapy
(Table 2) slightly fewer had left-sided than right-sided breast can-
cer (32.0% vs 32.7%) and, with such large numbers, this 0.7% differ-
ence was statistically significant (p = 0.05). When the analysis was
repeated separately for women with different characteristics, dif-
ferences of at least 1% in the proportion given radiotherapy for
left-sided versus right-sided disease were seen for women who
were: aged <50 years (1.0%), aged 70–79 years (1.1%), node posi-
tive (1.2%), given anthracyclines (1.9%), and for women given other
types of chemotherapy (2.3%). However, as the numbers of women
in the individual categories of these characteristics were smaller,
the differences were, in most cases, not statistically significant.
Among 4770 women who had prior heart disease recorded in the
NPR, the percentage of women given radiotherapy was identical
for women with left-sided and right-sided breast cancer. Among
3564 women receiving both radiotherapy and anthracyclines,
chemotherapy dose was available for 94%, all receiving epirubicin.
The median number of cycles was 7 (range 1–10), with a mean
cumulative dose of 721 mg, corresponding to 410 mg/m2 of epiru-
bicin. Anthracycline dose was unavailable for the remaining 6%,
who received either epirubicin or doxorubicin.
When the 19,464 women who received radiotherapy were sub-
divided according to patient and tumour characteristics, there was
no significant heterogeneity in the IRR, LvR according to year of
breast cancer radiotherapy, age at breast cancer radiotherapy,
nodal status, surgery, prior heart disease or adjuvant medical treat-
ment given (p = 0.33) (Table 3). There were, however, some notable
differences. For women given breast radiotherapy during
2001–2005 (i.e., the period in which anthracyclines were given)
the IRR, LvR was significantly increased (IRR, LvR: 1.15, 95% CI
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1.01–1.31), despite the fact that there was no increase in the pre-
vious decade (IRR, LvR: 1.01, 95% CI 0.90–1.14). The IRR, LvR was
significantly increased for women receiving anthracyclines (IRR,
LvR: 1.32, 95% CI 1.02–1.70, p = 0.03) and for women who did
not receive systemic therapy (IRR, LvR: 1.15, 95% CI 1.02–1.31,
p = 0.02). For women given chemotherapy other than anthracycli-
nes the IRR, LvR, was 1.13 but this did not reach statistical signifi-
cance. For women given endocrine therapy only, the IRR, LvR was
1.03 (95% CI 0.91–1.17).
When all 19,464 women who received radiotherapy were con-
sidered, there were significant increases in the IRR, LvR, for ischae-
mic heart disease (1.18, 95% CI 1.03–1.35), angina (1.22, 95% CI
1.00–1.49) and valvular heart disease (1.39, 95% CI 1.00–1.96)
(Table S1, panel a). These findings remained unchanged when the
18,130 women who did not have heart disease recorded in the
Danish NPR prior to their cancer diagnosis were considered
(Table S1, panel c). When 1134 women with heart disease recorded
in the Danish NPR prior to their cancer diagnosis were considered,
the IRR, LvR for all heart disease, was not significantly increased
(1.04, 95% CI 0.86–1.28, Table S1, panel b). For myocardial infarc-
tion, however, the IRR, LvR was doubled (2.05, 95% CI 1.00–4.44).
For all these three categories of women, the IRR, LvR, for heart fail-
ure was equal to or less than one (Table S1). Considering the 3564
women who were given both radiotherapy and anthracyclines,
many types of heart disease contributed to the increased IRR, LvR
(Table 4). For myocardial infarction, angina, and other and ill-
defined heart disease the IRR, LvR was more than doubled but only
for angina was the increase statistically significant when consid-
ered alone. For heart failure, the IRR, Lvs R was 1.51 (95% CI
0.64–3.56).
When women given both radiotherapy and anthracyclines were
subdivided according to the age at which radiotherapy was given,
the highest IRR, LvR was for women aged less than 50 years when
treated (IRR, LvR: 1.44, 95% CI 1.04–2.01, Fig. 2, panel a). However,
there was no significant trend in the IRR, LvR across the three age-
groups <50, 50–59, and 60+ years either for women who received
anthracyclines, or for all other women given radiotherapy (Fig. 2
panel b), or for all women given radiotherapy (Fig. 2 panel c).
The trend in the IRR, LvR, across time-periods 0–4, 5–9, and 10+
years after radiotherapy, was not significant for women given
anthracyclines and radiotherapy, for other women given radiother-
apy, or for all women given radiotherapy.
We examined the mortality rate ratios, left-sided vs right-sided,
by cause of death (Table S2). Only 12 women (3 left-sided and 9
right-sided) died of heart disease among those receiving both
radiotherapy and anthracyclines. The majority were registered as
Paents recorded in the Danish Breast Cancer 
Cooperave Group database 1977-2005: N=71,423
- Bilateral breast cancer or cancer of unknown laterality: N=5029
- Treatment did not include surgery: N=946
- Older than 80 years or younger than 20 years when diagnosed with breast cancer: N=5217
- Time from diagnosis of breast cancer to date of last follow-up less than 6 months: N=75
Paents remaining: 
N=60,156
Radiotherapy given: 
N=19,464
- Radiotherapy not indicated:  N=28,885 
- Radiotherapy indicated, but not recorded: N= 9138 
- Unknown: N=2669
Excluded: N=11,267
Radiotherapy not recorded: N=40,692
Fig. 1. Identification of study population.
Table 1
Incidence rate ratios, left-sided versus right-sided breast cancer, of all heart disease by laterality and radiotherapy status in 60,156 Danish patients, 1977–2005.
Radiotherapy status Number of events/Number of women Incidence rate ratio, left vs. right* (95% CI) p-valuey
Left-sided Right-sided
Radiotherapy given 1482/9915 1291/9549 1.11 (1.03–1.20) 0.005
Radiotherapy not recorded 4586/21,076 4088/19,616 1.03 (0.99–1.08) 0.12
RT not indicated 3333/14,952 2949/13,933 1.04 (0.99–1.10) 0.10
RT indicated, but not recorded 835/4707 800/4431 1.00 (0.91–1.11) 0.93
Unknown 418/1417 339/1252 1.07 (0.92–1.24) 0.37
All women 6068/30,991 5379/29,165 1.05 (1.01–1.09) 0.01
Analysis based on the first diagnosis of heart disease occurring six months or more after the breast cancer diagnosis.
RT: radiotherapy, CI: confidence interval.
* Stratified by calendar year, age, and time since breast cancer radiotherapy.
y Test of whether incidence rate ratio is equal to unity.
J.C. Rehammar et al. / Radiotherapy and Oncology 123 (2017) 299–305 301
Table 2
Characteristics of 19,464 Danish women given radiotherapy for early-stage breast cancer and of the total number of women diagnosed with the disease, by laterality of cancer.
Characteristic Women given radiotherapy/total number of women (%) p-value: %
left vs. % right
Left-sided Right-sided
Year of breast cancer radiotherapy
1977–1989 1882/10,835 (17.4) 1834/10,009 (18.3) 0.07
1990–2000 3540/13,220 (26.8) 3279/12,397 (26.4) 0.55
2001–2005 4493/6936 (64.8) 4436/6759 (65.6) 0.29
Age at breast cancer radiotherapy
<50 3352/8076 (41.5) 3344/7867 (42.5) 0.20
50–59 3185/8492 (37.5) 3088/8098 (38.1) 0.41
60–69 2666/8263 (32.3) 2409/7631 (31.6) 0.35
70–79 712/6160 (11.6) 708/5569 (12.7) 0.06
Nodal status
Negative 3701/15,879 (23.3) 3469/14,823 (23.4) 0.84
Positive 6147/13,710 (44.8) 6032/13,122 (46.0) 0.06
Unknown 67/1402 (4.8) 48/1220 (3.9) 0.29
Surgery
Mastectomy 4794/24,499 (19.6) 4581/22,854 (20.0) 0.19
Breast conserving surgery 5121/6492 (78.9) 4968/6311 (78.7) 0.82
Adjuvant medical treatment
Anthracyclines 1777/2517 (70.6) 1787/2466 (72.5) 0.14
Other chemotherapy 1746/3832 (45.6) 1735/3620 (47.9) 0.04
Endocrine therapy (no chemotherapy)* 3191/6425 (49.7) 3034/6116 (49.6) 0.95
No adjuvant medical treatment recordedy 3201/18,217 (17.6) 2993/16,963 (17.6) 0.86
Prior heart disease++
No 9230/28,543 (32.3) 8900/26,843 (33.2) 0.04
Yes 685/2448 (28.0) 649/2322 (28.0) 0.98
Total 9915/30,991 (32.0) 9549/29,165 (32.7) 0.05
* Included tamoxifen for 5 years to premenopausal women from 1999. For postmenopausal women, tamoxifen was given for 1 year from 1977 to 1995, and for 5 years from
1996. Aromatase inhibitors were introduced in a trial setting to postmenopausal women in 1998.
y Women recorded as having no adjuvant medical treatment (left: 2687/11,190, right: 2504/10,475); women who were allocated to a protocolled programme for systemic
therapy but with no records on systemic therapy (left: 275/675, right: 263/664); and women not allocated to a protocolled programme (left: 239/6352, right: 226/5824).
++ Women recorded in the Danish National Patient Register as having heart disease prior to diagnosis of breast cancer.
Table 3
Incidence rate ratios, left-sided versus right-sided breast cancer for all heart disease by various characteristics in 19,464 Danish women given radiotherapy.
Characteristic Number of events/number of
women
Incidence ratio,
left vs right*
(95% CI)
p-valuey p-value for
heterogeneity
Left Right
Year of breast cancer radiotherapy
1977–1989 402/1882 329/1834 1.24 (1.07–1.43) 0.004 0.09
1990–2000 561/3540 519/3279 1.01 (0.90–1.14) 0.86
2001–2005 519/4493 443/4436 1.15 (1.01–1.31) 0.03
Age at breast cancer radiotherapy (years)
<50 311/3352 302/3344 1.04 (0.89–1.23) 0.57 0.53
50–59 432/3185 382/3088 1.14 (0.99–1.31) 0.07
60–69 556/2666 434/2409 1.17 (1.03–1.32) 0.02
70–79 183/712 173/708 1.00 (0.81–1.23) 1.00
Nodal status
Negative 623/3701 517/3469 1.14 (1.01–1.28) 0.03 0.73
Positive 849/6147 769/6032 1.11 (1.00–1.22) 0.04
Unknown 10/67 5/48 1.66 (0.41–6.68) 0.48
Surgery
Mastectomy 701/4794 610/4581 1.13 (1.01–1.26) 0.03 0.73
Breast-conserving surgery 781/5121 681/4968 1.10 (0.99–1.22) 0.07
Adjuvant medical treatment
Anthracycline 140/1777 109/1787 1.32 (1.02–1.70) 0.03 0.33
Other chemotherapy 238/1746 215/1735 1.13 (0.94–1.37) 0.20
Endocrine therapy (no chemotherapy) 548/3191 491/3034 1.03 (0.91–1.17) 0.59
None reported 556/3201 476/2993 1.15 (1.02–1.31) 0.02
Prior heart disease
No 1255/9230 1084/8900 1.13 (1.04–1.22) 0.005 0.52
Yes 227/685 207/649 1.04 (0.86–1.28) 0.63
All women given radiotherapy 1482/9915 1291/9549 1.11 (1.03–1.20) 0.005
Analysis based on the first diagnosis of heart disease occurring six months or more after the breast cancer diagnosis.
* CI: Confidence Interval. Stratified by calendar year, age, and time since breast cancer radiotherapy.
y Test of whether incidence rate ratio is equal to unity.
 Excluding unknown category.
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having died from breast cancer which was the main contribution to
increased all-cause mortality ratio, left-sided versus right-sided of
1.26 (95% CI 1.10–1.44, p < 0.001). All-cause mortality did not differ
significantly between left- and right-sided breast cancers among
women receiving radiotherapy but not anthracyclines.
Discussion
This study confirms previous observations that women who
received radiotherapy for left-sided breast cancer had an increased
risk of subsequent heart disease compared with women who
received right-sided radiotherapy. The present study has examined
the radiation-related increase in heart disease according to the type
of systemic therapy given. It found that the proportional increase
among women irradiated for left-sided cancer compared with
right-sided cancer was highest for women who also received
chemotherapy with anthracyclines. Among women given both
anthracyclines and radiotherapy, the riskof heart diseasewashigher
in left-sided breast cancer compared with right-sided, even though
most of them had been treated since the year 2000 using modern
radiotherapy techniques. This suggests that chemotherapy with
anthracyclines may increase the effect of radiotherapy on the heart.
Initial exploratory analyses compared women who received
adjuvant therapy with those who did not and showed that women
who received adjuvant therapy had lower heart disease rates than
those who did not. This suggests that women who were at higher
risk of heart disease were less likely to receive radiotherapy and
adjuvant medical treatment, making comparisons of women who
did and did not receive such therapies biased. We have demon-
strated previously [4] that radiotherapy was associated with
reduced mortality from heart disease in women given breast-
conserving surgery and increased mortality among other women,
leading to selection bias if comparisons are made between irradi-
ated and unirradiated women. Such comparisons should not be
used to draw reliable conclusions as to the presence of any
radiation-related risk.
More than thirty studies, including around a quarter of a million
women irradiated for breast cancer during the past five decades,
have reported heart disease rates in women irradiated for left-
sided cancer compared with women irradiated for right-sided can-
cer [14]. In most of these studies, the left versus right cardiac event
rate ratio was greater than one and, in studies where specific types
of heart disease were examined, ischaemic heart disease was the
type most commonly affected. Consistent with these, in the pre-
sent study, among all women receiving radiotherapy during
1977–2005, the increase in heart disease among women irradiated
for left-sided breast cancer compared with right-sided cancer there
was a clear increase in ischaemic heart disease.
Anthracyclines were introduced into adjuvant chemotherapy as
part of a randomized trial for breast cancer patients in Denmark in
1990. It improves both breast cancer and overall survival [5,6].
However, several studies have shown that it can cause heart fail-
ure, with the risk increasing according to cumulative anthracycline
dose [7,8]. Most studies of radiation-related heart disease have not
included women who also received anthracyclines. The relation-
ship between heart radiation dose and subsequent ischaemic heart
disease has been studied in a population-based case-control study
in which individual cardiac doses were estimated. The major coro-
nary event rate increased approximately linearly with mean heart
radiation dose by 7.4% per Gray (95% CI, 2.9 to 14.5; p < 0.001) [15].
This study included very few women who also received anthracy-
clines. Information is therefore needed on whether the slope of this
dose response relationship is affected by exposure to anthracycli-
nes and on whether breast cancer radiotherapy given in combina-
tion with anthracyclines increase the risk of heart failure.
Strengths and limitations of the study
A strength of our study is that it is based on the entire popula-
tion of Danish breast cancer patients treated between 1977 and
2005. We included only women for whom there was a record that
radiotherapy had actually been given, rather than just being indi-
cated, as in previous studies from the DBCG. This will have
removed the downward bias in the IRR, LvR previously caused by
including women who were not, in fact, given radiotherapy. We
also were able to classify women according to the type of
chemotherapy given, enabling analyses of the cardiotoxic effects
of radiotherapy and anthracyclines combined. Even with these
stringent criteria, our study included nearly 20,000 women who
received radiotherapy, 3500 of whom also received anthracyclines.
Table 4
Incidence rate ratios, left-sided vs right-sided, in 3564 Danish women diagnosed with breast cancer during 1990–2005 who were given both radiotherapy and anthracyclines, by
type of heart disease.
Disease category (ICD-10 code) Number of events Left/right Incidence rate ratio, left vs. right* (95% CI) p-valuey
Ischaemic heart disease (I20-25) 32/19 1.71 (0.97–3.02) 0.07
Myocardial infarction (I21-23, I252) 7/3 2.29 (0.59–8.90) 0.23
Angina (I20) 21/9 2.36 (1.08–5.17) 0.03
Other ischaemic heart disease 4/7 0.58 (0.17–2.01) 0.39
Other heart disease (I00-52 excluding I20-25) 108/90 1.23 (0.93–1.64) 0.15
Hypertensive heart disease (I10-15) 14/21 0.59 (0.30–1.18) 0.14
Pulmonary embolism (I26-28) 11/8 1.33 (0.52–3.39) 0.55
Pericarditis (I01.0, I09.2, I30-32) 14/8 1.67 (0.69–4.03) 0.28
Valvular heart disease (I00-09, I01.0, I09.2, I34-39) 8/5 1.96 (0.59–6.52) 0.27
Other rheumatic heart disease (I00.9) 0/1 - -
Acute endocarditis (I33) 1/1 0.99 (0.06–15.9) 1.00
Myocardial disease (I40-43) 11/9 1.26 (0.52–3.03) 0.61
Conduction disorders & arrhythmias (I44-45, I47-49) 32/26 1.32 (0.78–2.22) 0.30
Cardiac arrest (I46) 1/1 1.06 (0.07–16.9) 0.97
Heart failure (I50) 13/9 1.51 (0.64–3.56) 0.34
Other & ill-defined heart disease (I51, I52) 3/1 2.68 (0.30–27.6) 0.36
All heart disease (I00-52) 140/109 1.32 (1.02–1.70) 0.03
1777 women had left-sided breast cancer and 1787 women had right-sided breast cancer. Analysis based on first diagnosis of heart disease six months or more after breast
cancer diagnosis.
Results for other categories of women are given in Table S1.
* CI: Confidence Interval. Stratified by calendar year, age, and time since breast cancer radiotherapy.
y Test of whether incidence rate ratio, left vs right, is equal to unity.
 Left-sided: aortic 1, mitral 5, pulmonary 2. Right-sided: aortic 2, mitral 3.
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Category
Events/Women
Left-sided Right-sided
Incidence rate ratio
:Left-sided      Right-sided ( 95% CI )
(a) Anthracycline given
Age at Radiotherapy (yr)   (Trend: p=0.31)
<50 88/1225 61/1254   1.44 (1.04-2.01)
50-59 40/471 34/459   1.24 (0.78-1.96)
60+ 12/81 14/74   0.92 (0.40-2.11)
Years since radiotherapy   (Trend: p=0.99)
0-4 84/1777 62/1787   1.35 (0.97-1.88)
5-9 43/1440 37/1521   1.23 (0.79-1.92)
10+ 13/717 10/758   1.51 (0.63-3.60)
(a) Subtotal 140/1777
109/
1787  1.32 (1.02-1.70)p = 0.03
(b) Anthracycline not given
Age at Radiotherapy (yr)   (Trend: p=0.13)
<50 223/2127 241/2090   0.94 (0.78-1.13)
50-59 392/2714 348/2629   1.13 (0.98-1.30)
60+ 727/3297 593/3043   1.13 (1.01-1.26)
Years since radiotherapy   (Trend: p=0.60)
0-4 547/8138 465/7762   1.11 (0.98-1.26)
5-9 366/6062 350/5835   0.99 (0.85-1.14)
10+ 429/3774 367/3583   1.18 (1.03-1.36)
(b) Subtotal 1342/8138
1182/
7762  1.10 (1.01-1.19)p = 0.02
(c) All with radiotherapy
Age at Radiotherapy (yr)   (Trend: p=0.40)
<50 311/3352 302/3344   1.04 (0.89-1.23)
50-59 432/3185 382/3088   1.14 (0.99-1.31)
60+ 739/3378 607/3117   1.13 (1.01-1.25)
Years since radiotherapy   (Trend: p=0.76)
0-4 631/9915 527/9549   1.14 (1.02-1.28)
5-9 409/7502 387/7356   1.01 (0.88-1.16)
10+ 442/4491 377/4341   1.19 (1.03-1.37)
(c) Total 1482/9915
1291/
9549  1.11 (1.03-1.20)p = 0.005
0.0 0.5 1.0 1.5 2.0
Left-sided better Left-sided worse
Fig. 2. Incidence rate ratios, left-sided versus right-sided breast cancer, of all heart disease in 19,464 women given radiotherapy by age at radiotherapy, years since
radiotherapy, and whether or not anthracycline chemotherapy was given.
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The comparison of cardiac events in women irradiated for left-
sided versus right-sided breast cancer represents a comparison of
higher versus lower radiation dose. Up until 2002 radiotherapy
regimens in Denmark were identical in women with left-sided
and right-sided breast cancer. During 2003–2005 some women
were entered into the DBCG-IMN study in which internal mam-
mary node radiation was given to women with right-sided but
not with left-sided breast cancer [16]. This may be one of the rea-
sons for the increased breast cancer and all-cause mortality rates
among women with left-sided cancer who received both radiother-
apy and anthracyclines (Table S2). Even for the women in this
study, however, cardiac doses were higher in women with left-
sided than right-sided breast cancer. In most countries, the ratio
of dose in left-sided versus right-sided breast cancer varies sub-
stantially according to the regions irradiated [17]. We did not have
heart dose information for the individual women in our study.
Nevertheless, a study of heart doses from Danish breast cancer reg-
imens used during 1977–2001 has shown that the average mean
heart dose was around 6 Gy for left-sided RT and around 2–3 Gy
for right-sided radiotherapy [18] though with considerable varia-
tion from 1 Gy to 8 Gy for left-sided tangential radiotherapy [19].
In this study, the number of women receiving both radiother-
apy and anthracyclines was limited and the length of follow-up
was relatively short which is clearly a limitation of our study. In
addition, women selected for chemotherapy with anthracyclines
are less likely to suffer from heart disease at diagnosis. The study
also has some further limitations. First, the cardiology records of
patients recorded with heart disease were not examined to confirm
diagnoses from the Danish NPR. Second, for angina it is possible
that women who developed chest pain after receiving left-sided
radiotherapy may have been more frequently investigated, and
diagnosed with angina than women receiving right-sided radio-
therapy. This may have affected our IRR, LvR ratios for angina.
Third, we were not able to examine the effect of trastuzumab
because no women in our study received it.
Implications
Our results have implications for assessment of the risk of
today’s breast cancer radiotherapy. They confirm the excess of
ischaemic heart disease from breast cancer radiotherapy seen in
previous studies and suggest that the effect of radiotherapy on
the heart may be increased by anthracyclines. From a clinical point
of view, every possible effort should be made to reduce the dose to
the heart in breast cancer radiotherapy but without compromising
the coverage of the target, thus maintaining the beneficial effect of
radiotherapy.
Conclusion
Radiotherapy for left-sided breast cancer is associated with a
higher risk of heart disease than for right-sided with the largest
increases seen in women who also received anthracycline-
containing chemotherapy.
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